The effect of donepezil in comparison with conventional treatment on cognitive functioning and the performance of the patient in a prospective cohort of patients with Alzheimer's disease treated in routine clinical practice in Spain;Efecto del donepecilo comparado con el tratamiento convencional en la función cognitiva y el rendimiento del paciente en una cohorte prospectiva de pacientes con enfermedad de Alzheimer tratados en la práctica clínica habitual en España

Revista de Neurologia

Volumn 51, Issue 10, 2010, Pages 577-588

  López Pousa, Secundino ^a   Bermejo Pareja, Félix ^b   Frank, Ana ^c   Hernández, Francisco ^d   León, Teresa ^e   Rejas Gutiérrez, Javier ^e   Bermejo Pareja, F ^b   Coduras, A ^f   Del Llano, J ^f   Lopez Arrieta J ^f   Leon T ^e   Lopez Pousa S ^a   Rejas Gutierrez J ^e  

^a HOSPITAL SANTA CATERINA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d European Biometrics Institute   (Spain)

^e PFIZER INC   (United States)

^f Fundacion Gaspar Casal   (Spain)

Author keywords

ACEI; Alzheimer's disease; Cognitive functioning; Donepezil; Performance; Routine clinical practice

Indexed keywords

DONEPEZIL;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; COST OF ILLNESS; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MULTICENTER STUDY; POST HOC ANALYSIS; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; SECONDARY ANALYSIS; SINGLE BLIND PROCEDURE; SPAIN; TREATMENT OUTCOME;

EID: 78649811337     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5110.2009562     Document Type: Article

References (46)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-7. (Pubitemid 41797645)
2. Santos-Franco JA, Barquet-Platón EI, Mercado-Pimentel R, Ortiz-Velázquez RI, Cardona-Cabrera S, Otero-Siliceo E. Demencias potencialmente reversibles no quirúrgicas. Rev Neurol 2005; 40: 54-60.
3. Argimón JM, Limón E, Vila J, Cabezas C. Health-related quality of life in careers of patients with dementia. Fam Pract 2004; 21: 454-7.
4. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006: CD005593.
5. Hansen RA, Gartlehner G, Lohr KN, Kaufer DI. Functional outcomes of drug treatment in Alzheimer's disease: a systematic review and meta-analysis. Drugs Aging 2007; 24: 155-67.
6. Livingston G, Katona C. How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis. Int J Geriatr Psychiatry 2000; 15: 203-7.
7. Boada-Rovira M, Brodaty H, Cras P, Baloyannis S, Emre M, Zhang R, et al. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study. Drugs Aging 2004; 21: 43-53.
8. Hager K, Calabrese P, Frolich L, Gobel C, Berger FM. An observational clinical study of the efficacy and tolerability of donepezil in the treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 2003; 15: 189-98.
9. Cameron I, Curran S, Newton P, Petty D, Wattis J. Use of donepezil for the treatment of mild-moderate Alzheimer's disease: an audit of the assessment and treatment of patients in routine clinical practice. Int J Geriatr Psychiatry 2000; 15: 887-91.
10. Wallin AK, Andreasen N, Eriksson S, Batsman S, Nasman B, Ekdahl A, et al. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord 2007; 23: 150-60.
11. Bartorelli L, Giraldi C, Saccardo M, Cammarata S, Bottini G, Fasanaro AM, et al. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Curr Med Res Opin 2005; 21: 1809-18. (Pubitemid 41667249)
12. Schmidt R, Lechner A, Petrovic K. Rivastigmine in outpatient services: experience of 114 neurologists in Austria. Int Clin Psychopharmacol 2002; 17: 81-5.
13. González-Gutiérrez JL, Gobartt AL. Hábitos de prescripción de rivastigmina en solución en pacientes con demencia de tipo Alzheimer en España (estudio RIVASOL). Rev Neurol 2007; 44: 705-10.
14. Patterson CE, Passmore AP, Crawford VL. A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease. Int J Clin Pract 2004; 58: 144-8.
15. Brodaty H, Woodward M, Boundy K, Barnes N, Allen G. A naturalistic study of galantamine for Alzheimer's disease. CNS Drugs 2006; 20: 935-43.
16. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006: CD003154.
17. Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002; 56: 441-6.
18. Fuschillo C, La Pia S, Campana F, Pinto A, De Simone L. Cognitive deficits in Alzheimer's disease: treatment with acetylcholinesterase inhibitor agents. Arch Gerontol Geriatr Suppl 2001; 7: 151-8.
19. Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003; 20: 777-89.
20. Jones RW, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19: 58-67.
21. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005; 21: 1317-27.
22. López-Pousa S, Turón-Estrada A, Garre-Olmo J, Pericot-Nierga I, Lozano-Gallego M, Vilalta-Franch M, et al. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period. Dement Geriatr Cogn Disord 2005; 19: 189-95.
23. Mossello E, Tonon E, Caleri V, Tilli S, Cantini C, Cavallini MC, et al. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a 'real world' study. Arch Gerontol Geriatr Suppl 2004; 9: 297-307.
24. Aguglia E, Onor ML, Saina M, Maso E. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin 2004; 20: 1747-52.
25. Caffarra P, Vezzadini G, Copelli S, Dieci F, Messa G, Nonis E, et al. Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors. Acta Biomed 2007; 78: 16-21.
26. Coduras A, Rabasa I, Frank A, Bermejo-Pareja F, López-Pousa S, López-Arrieta JM, et al. Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study. J Alzheimers Dis 2010; 19: 601-15.
27. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43:2412-2414.
28. Blesa R, Pujol M, Aguilar M, Santacruz P, Bertrán-Serra I, Hernández G, et al. Clinical validity of the 'mini-mental state' for Spanish speaking communities. Neuropsychologia 2001; 39: 1150-7.
29. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114: 797-811.
30. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 1980; 20: 649-55.
31. Ruiz M, Rejas J, Soto J, Pardo A, Rebollo I. Adaptation and validation of the Health Utilities Index Mark 3 into Spanish and correction norms for Spanish population. Med Clin (Barc) 2003; 120: 89-96.
32. Sevilla C, Jiménez-Caballero PE, Alfonso V. Donepecilo bucodispersable: ¿están los cuidadores principales del paciente con enfermedad de Alzheimer más satisfechos que con la formulación tradicional de donepecilo? Rev Neurol 2009; 49: 451-7.
33. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481-8.
34. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-95.
35. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000; 10: 195-203.
36. Agüera-Ortiz LF, Grupo de investigadores del estudio MEMORY. La memantina en el tratamiento farmacológico de la enfermedad de Alzheimer moderadamente grave a grave en España (estudio MEMORY). Rev Neurol 2010; 51: 525-34.
37. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994; 151: 390-6.
38. Lopez OL, Becker JT, Saxton J, Sweet RA, Klunk W, DeKosky ST. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc 2005; 53: 83-7. (Pubitemid 41647636)
39. McCarten JR, Rottunda SJ, Kuskowski MA. Change in the mini-mental state exam in Alzheimer's disease over 2 years: the experience of a dementia clinic. J Alzheimers Dis 2004; 6: 11-5.
40. Wattmo C, Wallin AK, Londos E, Minthon L. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. Alzheimer Dis Assoc Disord 2010; Sep 16. [Epub ahead of print].
41. Peña-Casanova J, Monllau A, Bohm P, Blesa-González R, Aguilar-Barberá M, Sol JM, et al. Correlations between cognition and function in Alzheimer's disease: based on the abbreviated Barcelona Test (a-BT). Neurologia 2005; 20: 4-8.
42. Bermejo F, Robles A, López-Pousa S, Masramón X, Rejas J, León T. Calidad de vida (CVRS) en la enfermedad de Alzheimer (EA) y sobrecarga del cuidador en una cohorte de pacientes tratados con donepecilo durante 2 años en condiciones de práctica médica habitual: resultados del estudio Donald.es [abstract]. Neurologia 2006; 21: 622.
43. Winblad B, Jones RW, Wirth Y, Stoffler A, Mobius HJ. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007; 24: 20-7.
44. Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, et al. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Curr Med Res Opin 2006; 22: 483-94.
45. Gil-Néciga E, Gobartt AL, Grupo de investigadores del estudio TRAIN. Patrón de tratamiento de la enfermedad de Alzheimer con inhibidores colinesterásicos (estudio TRAIN). Rev Neurol 2008; 46: 461-4.
46. Agüera-Ortiz LF, Ramos-García M, Gobartt AL, Grupo de investigadores del estudio SCALEX. Estudio comparativo de la efectividad y tolerabilidad de un procedimiento de escalado lento de dosis de rivastigmina en pacientes con demencia tipo Alzheimer leve o moderada: estudio SCALEX. Rev Neurol 2008; 46: 517-24.